Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation

被引:387
作者
Fang, MC
Chang, YC
Hylek, EM
Rosand, J
Greenberg, SM
Go, AS
Singer, DE
机构
[1] Univ Calif San Francisco, Div Gen Internal Med, Hospitalist Grp, San Francisco, CA 94143 USA
[2] Kaiser Permanente, Oakland, CA USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
关键词
D O I
10.7326/0003-4819-141-10-200411160-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The risk for atrial fibrillation-associated stroke increases at low anticoagulation intensities. However, higher intensities increase hemorrhage risk. Optimal use of warfarin for atrial fibrillation requires precise information on the risk for intracranial hemorrhage as a function of patient age and anticoagulation intensity. Objective: To examine the relationship of age, anticoagulation intensity, and risk for intracranial hemorrhage. Design: Case-control study. Setting: Academic medical center. Patients: 170 case-patients who developed intracranial hemorrhage during warfarin therapy and 1020 matched controls who did not; both case-patients and controls were taking warfarin for atrial fibrillation. Measurements: The authors performed multivariable conditional logistic regression to determine the odds of intracranial hemorrhage with regard to age and international normalized ratio (INR), controlling for comorbid conditions and aspirin use. Results: Case-patients were older than controls (median age, 78 years vs. 75 years; P < 0.001) and had higher median INRs (2.7 vs. 2.3; P < 0.001). The risk for intracranial hemorrhage increased at 85 years of age or older (adjusted odds ratio, 2.5 [95% CI, 1.3 to 4.7]; referent age, 70 to 74 years) and at an INR range of 3.5 to 3.9 (adjusted odds ratio, 4.6 [CI, 2.3 to 9.4]; referent INR, 2.0 to 3.0). The risk for intracranial hemorrhage at INRs less than 2.0 did not differ statistically from the risk at INRs of 2.0 to 3.0 (adjusted odds ratio, 1.3 [CI, 0.8 to 2.2]). Limitations: Although duration of anticoagulation has been associated with hemorrhage in other studies, the current study could not control for this potential confounder. Conclusions: The risk for intracranial hemorrhage increases at age 85 years. International normalized ratios less than 2.0 were not associated with lower risk for intracranial hemorrhage compared with INRs between 2.0 and 3.0. Therefore, anticoagulation management should focus on maintaining INRs in the 2.0 to 3.0 range, even in elderly patients with atrial fibrillation, rather than targeting INRs less than 2.0. Similarly, INRs of 3.5 or greater should be avoided.
引用
收藏
页码:745 / 752
页数:8
相关论文
共 47 条
[1]  
[Anonymous], 2001, CIRCULATION, V104, P2118
[2]  
[Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
[3]   Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation [J].
Antani, MR ;
Beyth, RJ ;
Covinsky, KE ;
Anderson, PA ;
Miller, DG ;
Cebul, RD ;
Quinn, LM ;
Landefeld, CS .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1996, 11 (12) :713-720
[4]   Clinical features and functional outcome of intracerebral hemorrhage in patients aged 85 and older [J].
Arboix, A ;
Vall-Llosera, A ;
García-Eroles, L ;
Massons, J ;
Oliveres, M ;
Targa, C .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (03) :449-454
[5]   Prediction of functional outcome and in-hospital mortality after admission with oral anticoagulant-related intracerebral hemorrhage [J].
Berwaerts, J ;
Dijkhuizen, RS ;
Robb, PJ ;
Webster, J .
STROKE, 2000, 31 (11) :2558-2562
[6]   Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages [J].
Berwaerts, J ;
Webster, J .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2000, 93 (08) :513-521
[7]   Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? [J].
Beyth, RJ ;
Antani, MR ;
Covinsky, KE ;
Miller, DG ;
Chren, MM ;
Quinn, LM ;
Landefeld, CS .
JOURNAL OF GENERAL INTERNAL MEDICINE, 1996, 11 (12) :721-728
[8]   Why do patients with atrial fibrillation not receive warfarin? [J].
Bungard, TJ ;
Ghali, WA ;
Teo, KK ;
McAlister, FA ;
Tsuyuki, RT .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (01) :41-46
[9]   OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES [J].
CANNEGIETER, SC ;
ROSENDAAL, FR ;
WINTZEN, AR ;
VANDERMEER, FJM ;
VANDENBROUCKE, JP ;
BRIET, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (01) :11-17
[10]   National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation [J].
Fang, MC ;
Stafford, RS ;
Ruskin, JN ;
Singer, DE .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (01) :55-60